fect was reported even in anuric hemodialysis (HD) patients. This increase in potassium serum levels was attributed to a reduction in the colonic excretion of potassium and likely to be intensified during the interdialytic period. However, dialysis patients may benefit from renin-angiotensin aldosterone system (RAAS) inhibitors, including angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB). In particular, the use of ACEis and ARBs in peritoneal dialysis (PD) patients seems to have a positive impact on cardiovascular disease, residual renal function (RRF), and on the peritoneal membrane structure [6] [7] [8] [9] [10] [11] [12] .
The effect of RAAS inhibition on PD patients is likely different from HD patients, given the absence of the large interdialytic period common to HD. This was suggested by a small single-center study that analyzed 29 patients using a crossover design [13] . Nevertheless, according to our knowledge, no other study has confirmed this finding. Therefore, our study aims to analyze the effect of ACEis and ARBs on potassium serum levels of a nationwide PD cohort.
Methods
BRAZPD II is a national representative cohort study that included patients from 122 Brazilian centers. Clinical and laboratorial data were prospectively collected monthly from December 2004 to January 2011 using specific software developed for this objective. Details about study design and general characteristics of the population have been previously published [14] . The cohort comprises around 65% of all PD patients of the country along the study period; all patients signed their informed consent and local Ethical Committees of all participating centers approved the study.
This analysis included incident patients on PD, who had an ACEi or ARB prescribed for at least 3 months and a similar period of time without the medication. All patients should have all 3 measures of potassium in both time periods (before and after switch); otherwise, they were excluded from the analysis. Therefore, 4 subgroups were included: (I) patients using ACEi only during the first period of the study; (II) using ACEi only in the second period; (III) using ARB only during the first period; and (IV) ARB prescribed only during the second study period. We compared potassium serum levels before and after the modality switch. Patients using ARB and ACEi concomitantly were not included in the study. The presence of RRF was defined as a daily urinary output >100 mL.
Statistical Analysis
Continuous variables were expressed as mean ± SD or median and interquartile range, while categorical variables (e.g., gender, race, primary renal disease, presence of comorbid conditions, initial therapy, current PD modality) were expressed as frequencies or percentages. The χ 2 , t test, or Wilcoxon were used, as appropriate, to compare demographic and clinical characteristics at baseline. The main outcome, changes in potassium serum levels, was compared using 2 statistical approaches: one using the non-parametric Wilcoxon test for repeated measures; and given a similar characteristic to a crossover study in this analysis, we also used a new and specific Stata command that provide values for carryover, sequence, period, and intervention effects (pkcross). Statistical significance was set at the level of p < 0.05. All analyses were performed using STATA 14.0.
Results
We identified 636 patients that met the inclusion criteria, of whom 242 were in Group I, 243 in Group II, 66 in Group III, and 84 in Group IV. Patients' mean age was 58.6 ± 16.1 years, 44.0% were male, 43.5% were diabetics, and 45.7% had history of previous HD. Demographic characteristics by subgroups are presented in Table 1 . Importantly, no patient analyzed included in this study changed PD modality, which could have affected potassium serum levels per se. In addition, Table 2 depicts the prevalence of patients with potassium serum levels above 5.5 mEq/L before and after changing the prescription of the study population and also according to the RRF status.
Model I -Nonparametric Paired Test (Wilcoxon) -Comparison of Means before and after Switch Prescription
Mean potassium serum levels at the first phase of the study for Groups I, II, III, and IV were, respectively, 4.46 ± 0.79, 4.33 ± 0.78, 4.41 ± 0.63, and 4.44 ± 0.56. Changes in mean potassium serum levels for Groups I, II, III, and IV were -0.10 ± 0.60, 0.02 ± 0.56, -0.06 ± 0.46, and 0.03 ± 0.50, respectively. The probability that the mean difference was different of zero was 0.01 (Group I), 0.59 (Group II), 0.26 (Group III), and 0.52 (Group IV). Figure 1 depicts a scatterplot showing the number of patients who had an increase (above the diagonal line) or decrease (below the line) in potassium serum levels after the transition, while Figure 2 depicts the mean values and SD of all 4 groups along the 6 months of follow-up.
Model II -Crossover Analysis (pkcrossStata Command)
In this model, we compared the differences in the moment immediately before changing the prescription with the values obtained after 3 months of the change. Table 3 shows the change in potassium serum levels by groups. A small reduction of 0.17 mEq/L was observed in the subgroup of patients that had ACEi interrupted after at least 3 months of therapy (Group I). This fall was slightly more pronounced in patients with RRF at baseline compared with anuric patients (-0.22 vs. -0.09 mEq/L). When an ACEi was introduced after the 3 initial months without the medication (Group II), the effect on potassium was also practically none and there is no difference between those patients with and without RRF (0.05 vs. 0.05 mEq/L).
Regarding ARB, its discontinuation (Group III) had no effect on mean potassium levels (-0.01 mEq/L). Patients with RRF had a small reduction of -0.20 ± 0.83 mEq/L in potassium levels, while a small increase of 0.22 ± 9 was observed in the anuric patients.
Discussion
This is the largest cohort study to analyze the impact of the use of ACEi and ARB on potassium serum levels. Our findings suggest that the clinical effect of these drugs on potassium serum levels of PD patients is not significant and unlikely to cause any harm, independently of RRF.
Hyperkalemia is a well-known clinical complication of patients with kidney dysfunction. It may affect up to 40% of patients with CKD stage IV and can be accentuated with the use of inhibitors of the RAAS [15] . This effect occurs frequently with both ACEi and ARBs but seems to be more pronounced with ACEi than with ARB as shown in a recent nested-case control study [15] .
The higher risk for hyperkalemia persists even after the initiation of HD and can be twice as great among those taking ACEi or ARB compared to other patients taking only anti-hypertensive drugs of other classes [4] . This effect that increases the prevalence of hyperkalemia was observed even in anuric patients and was attributed to a reduction in the gastrointestinal excretion or even in a disturbance of the cellular uptake of potassium acting during the interdialytic period [16] . In contrast to HD, PD is characterized as a continuous therapy, which in turn allows for a continuous removal of potassium and a more effective removal of this electrolyte in the long term as already observed in several large cohorts that compared the prevalence of potassium disturbances in both methods [1] . Our hypothesis was that the use of inhibitors of the RAAS in PD patients might be associated with a lower risk for hyperkalemia.
To the best of our knowledge, the only study to evaluate the effect of these drugs on serum potassium was a small single-center study with 29 patients and the authors found no increased risk for hyperkalemia [13] . However, this intervention was not tested in larger populations, particularly in cohorts with good external validity. Our study, more robust in terms of sample size, confirmed that these medications did not significantly increase potassium serum levels in daily clinical practice. In Figure 2 , which depicts the changes in potassium serum levels for all patients, we can see a uniform distribution of patients that had an increase (above the diagonal line) or decrease (below diagonal line) in the serum potassium level with the use of each drug. Our findings were consistent even across the subgroup of patients divided according to the presence or absence of RRF.
Our study presents some important strengths, including a large sample size, the crossover design with a specific statistical analysis for this type of design, and the ability to capture the impact of daily clinical practice prescription of ACEi/ARB on potassium serum levels. Nevertheless, this study also presents some limitations, such as the lack of information about the reasons for the initiation or interruption of ACEi/ARB, the dose prescribed of these drugs or information about other drugs that could have had an influence on potassium serum levels including potassium supplements. In addition, we do not have nutritional information that could provide data on daily potassium intake or information on Kt/V or weekly CCT. Finally, RRF was measured only at baseline.
In conclusion, the use of ACEi and ARB seems to be safe in terms of the risks involved in the development of hyperkalemia for stable PD patients independently of RRF.
